https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12377 Sat 24 Mar 2018 10:34:56 AEDT ]]> Longitudinal direct medical costs associated with constipation in women https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12372 Sat 24 Mar 2018 10:34:56 AEDT ]]> Multiple functional gastrointestinal disorders linked to gastroesophageal reflux and somatization: a population-based study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31481 Sat 24 Mar 2018 08:45:13 AEDT ]]> Overdiagnosis of gastro-esophageal reflux disease and underdiagnosis of functional dyspepsia in a USA community https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20759 Sat 24 Mar 2018 08:00:26 AEDT ]]> Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19187 0.5); however, significant treatment effects (p < 0.05) on the number of acid reflux episodes were observed with lower values on pumosetrag 0.2mg (10.8 ± 1.1), 0.5mg (9.5 ± 1.1), and 0.8mg (9.9 ± 1.1) compared with placebo (13.3 ± 1.1). Significant treatment effects (p < 0.05) were also observed for the percentage of time pH was <4, with less time for pumosetrag at 0.5mg (10%) and 0.8mg (10%) compared with placebo (16%). Conclusions & Inferences: In GERD, the partial 5HT3 agonist pumosetrag significantly reduced the rate of acid reflux events but did not result in a significant change in LESP or symptomatic improvement over a 1-week treatment period.]]> Sat 24 Mar 2018 07:55:04 AEDT ]]> Associations between medication use and functional gastrointestinal disorders: a population-based study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19975 Sat 24 Mar 2018 07:54:30 AEDT ]]> The effects of ageing on the onset and disappearance of unexplained abdominal pain: a population-based study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21324 Sat 24 Mar 2018 07:52:50 AEDT ]]> Cyclic vomiting syndrome and functional vomiting in adults: association with cannabinoid use in males https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22240 Sat 24 Mar 2018 07:17:36 AEDT ]]> Overlap of dyspepsia and gastroesophageal reflux in the general population: one disease or distinct entities? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22241 Sat 24 Mar 2018 07:17:31 AEDT ]]> Prevalence and risk factors for dysphagia: a USA community study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19834 Fri 14 Aug 2015 13:26:22 AEST ]]>